VERISILICON
14.3.2024 01:01:27 CET | Business Wire | Press release
VeriSilicon (688521.SH) today announced the integration of its Image Signal Processor (ISP) IP ISP8000, DeWarp Processor IP DW200, and 2.5D Graphics Processor Unit (GPU) IP GCNanoV into Canaan’s K230 chip, the world’s first commercial mass production edge AIoT chip supporting the RISC-V Vector 1.0 standard. This collaboration marks a significant advancement in the high-precision, low-latency edge AIoT solutions for a wide range of intelligent products, such as large-model and multimodal input edge terminals, 3D-structured light perception modules, interactive robots, open-source hardwares, as well as hardwares for smart manufacturing, smart home solutions and AI education.
VeriSilicon’s ISP8000 IP is capable of real-time processing of three or more streams of high-definition video. Its 20-bit depth pipeline architecture supports advanced image processing algorithms such as triple-exposure High Dynamic Range (HDR) and 3D Noise Reduction (3DNR). ISP8000’s optimized software collaborates seamlessly with the RISC-V processors to efficiently manage and schedule system resources. On the K230 chip, leveraging the RT-Thread real-time operating system and the performance and power advantages of the RISC-V processors, ISP8000 can perform real-time scheduling and efficiently run software under a dual-core processor architecture. It is perfectly compatible with the K230 Software Development Kit (SDK), supporting RTOS and Linux dual operating systems, achieving an optimal balance between real-time and non-real-time operations.
VeriSilicon’s DW200 IP not only precisely corrects distortions in wide-angle or fisheye lens, but also supports multi-channel downscaling output through low-bandwidth direct link mode, enriching user application scenarios, and is particularly suited for AI applications with diverse spatial output requirements. For MCU/MPU devices, VeriSilicon’s low-power 2.5D GPU IP delivers high-performance and high-quality vector graphics processing capabilities along with superior image output.
Hong-Gang Wang, VP of research and development at Canaan said, “Leveraging VeriSilicon’s advanced pixel processing IP portfolio, our RISC-V based K230 achieved leading performance and image quality compared with other edge AIoT SoCs in its class. This enables more edge device vendors to develop innovative products with broader market applications. VeriSilicon’s ISP is one of the key factors driving innovation in our edge AIoT SoCs.”
“RISC-V is increasingly important in embedded products. We have partnered with all leading RISC-V CPU IP vendors to ensure our comprehensive Glass-to-Glass (from camera-in to display-out) intelligent pixel processing IP portfolio collaborates seamlessly and efficiently with RISC-V architectures,” said Wei-Jin Dai, Executive VP and GM of IP Division at VeriSilicon. “Through our close collaboration with Canaan, the edge AIoT SoC K230 has achieved high image quality while maintaining low power consumption and latency. Moreover, K230 can support multiple sensors leveraging the advanced Multi-Context Management (MCM) feature of ISP8000, further enhancing its market competitiveness.”
About Canaan Inc.
Canaan Inc. (Nasdaq: CAN) is a leading provider of high-performance ASIC chips. With a diversified strategy centered on “blockchain + AI”, Canaan is dedicated to the research and development of high-performance ASIC computing chips, AI chips, and devices. As a Nasdaq-listed company, Canaan holds the distinction of being the world’s “first blockchain stock company” and the initial Chinese firm with independent intellectual property in AI chips to be listed in the US. Canaan is committed to harnessing ASIC technology to achieve its mission of “Super Computing Is What We Do, Social Enrichment is Why We Do”, positioning itself as a leader in high-performance computing for blockchain and AI.
For more information, please visit: canaan.io
About VeriSilicon
VeriSilicon is committed to providing customers with platform-based, all-around, one-stop custom silicon services and semiconductor IP licensing services leveraging its in-house semiconductor IP. For more information, please visit: www.verisilicon.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240313405660/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Yubico Appoints Poupak Modirassari Enbom as Chief Marketing Officer to Accelerate Global Momentum and Drive Market Leadership30.3.2026 15:00:00 CEST | Press release
Yubico (NASDAQ STOCKHOLM: YUBICO), the creator of the most secure passkeys and a leading provider of hardware authentication security keys, today announced the appointment of Poupak Enbom as Chief Marketing Officer (CMO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330278027/en/ Enbom joins Yubico at a pivotal moment as organizations worldwide accelerate the shift to phishing-resistant authentication and modern identity security in the age of AI. “We’re excited to welcome Poupak to Yubico,” said Jerrod Chong, acting chief executive officer, Yubico. “As the threat landscape evolves with AI-driven attacks and increasing automation, organizations are rethinking how they secure digital identities of both humans and AI agents at scale. She brings a unique combination of technical depth, global leadership, and customer-first mindset that will help us continue to expand our impact and support our customers and partners around
Westinghouse Celebrates Record-breaking 80 Years of Nuclear Fuel Manufacture at Springfields30.3.2026 14:00:00 CEST | Press release
Fuel manufactured at Springfields has generated enough energy to supply the UK’s electricity demand for 26 years, avoiding the emission of nearly 3 billion tonnes of CO2 The Westinghouse Springfields facility in Lancashire, UK, has marked a significant milestone as the oldest continuous nuclear fuel manufacturing site in the world, starting from its original license on the 28th, March 1946. The site was chosen by the UK Government to develop nuclear fuel for the world’s earliest civil nuclear power stations, as well as subsequent Magnox and Advanced Gas Reactors (AGR) reactors. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330135973/en/ From left to right: Sophie Lemaire; Marc Chevrel; Rory O'Neill; Craig Boothby; and Robert Gofton, CEO at Nuclear Institute Across the last eight decades, the Springfields site has supported the UK nuclear fleet, manufacturing more than eight million AGR pins, sintering and pressing over 5
HistoSonics Treats First Patients Evaluating the Edison® Histotripsy System for the Treatment of Benign Prostatic Hyperplasia (BPH)30.3.2026 14:00:00 CEST | Press release
HistoSonics, the developer of the Edison® Histotripsy System and novel histotripsy therapy platform, today announced the successful treatments of the first patients in WOLVERINE, a prospective feasibility trial evaluating the Edison® Histotripsy System for the treatment of benign prostatic hyperplasia (BPH) at Prince of Wales Hospital in Hong Kong, a teaching hospital for The Chinese University of Hong Kong. The Edison System is a novel, non-invasive, image guided platform that uses the mechanical properties of focused ultrasound, called histotripsy, to destroy unwanted tissue without the need for invasive procedures, and with potentially fewer side effects than traditional, invasive therapies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260330349844/en/ HistoSonics Non-Invasive Edison Histotripsy System. Image credit: HistoSonics WOLVERINE is a prospective, multi-center, single-arm feasibility trial designed to evaluate
Biocytogen Grants Taisho Pharmaceutical a License to its RenNano® Fully Human Heavy Chain-Only Antibody Discovery Platform30.3.2026 13:00:00 CEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (Biocytogen, SSE: 688796; HKEX: 02315), a global biotechnology company that drives the research and development of novel antibody-based drugs with innovative technologies, today announced that it has entered into a platform license agreement with Taisho Pharmaceutical Co., Ltd. (“Taisho”), granting Taisho the right to access and use Biocytogen’s proprietary RenNano® fully human heavy chain-only antibody (HCAbs) discovery platform for its internal research and development programs. Under the terms of the agreement, Taisho will leverage RenNano® mice to enable the generation and screening of fully human HCAbs in vivo and to support downstream research associated with antibody discovery. Financial terms of the agreement have not been disclosed. “We are very pleased to enter into this collaboration with Taisho,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “RenNano® is a robust and powerful fully human VHH discovery platform that pro
Meiji Seika Pharma Invests in Centivax to Develop Next Generation Universal Vaccine Platform30.3.2026 13:00:00 CEST | Press release
Meiji Seika Pharma Co., Ltd. (Head Office: Chuo-ku, Tokyo, President and Representative Director: Toshiaki Nagasato) today announced a strategic investment in Centivax, Inc. (Head Office: South San Francisco, CA, USA), a biotechnology company developing next-generation vaccines and therapies for universal protection against highly diverse targets. Centivax’s lead program includes a universal seasonal influenza vaccine (Centi-Flu 01) currently in a Phase 1 clinical study. Unlike conventional seasonal flu vaccines, which must be manufactured annually based on recommended candidate vaccine viruses, Centivax’s platform focuses both antibody and cellular immune responses on conserved regions of the influenza virus that cannot mutate and are shared across strains and distant subtypes. This approach aims to generate broad, consistent, and durable immunity against both seasonal and pandemic influenza. Meiji’s strategic investment aims to accelerate the advancement of Centi-Flu 01 and further a
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom